Matthew Wagoner, PhD

Graduation: 08/2010
Advisor: Roopra, Avtar
Current Position: Discovery Safety Scientist
Global Safety Assessment
AstraZeneca Pharmaceuticals
Alderley Edge, England
Research Interest: Molecular biology, biomarkers, bioinfortmatics, transcriptional profiling
Email: matthew (dot) wagoner (at) astrazeneca (dot) com

Alumni News

  • As a molecular toxicologist, I help to reduce the safety risks associated with our oncology and infection portfolios using bioinformatics and custom in vitro assays.
  • My postdoctoral research centered around developing our knowledge of protein and miRNA biomarkers of toxicity at AstraZeneca
  • My PhD centered around investigating mechanisms of signal transduction and tumor biology using molecular biology, with an emphasis on protein, DNA and RNA manipulation and detection.
  • Using transcriptional profiling, along with other bioinformatic techniques, we identified never before recognized roles for the tumor suppressor REST in human tumors.
  • More recently, we have been modeling the molecular changes we’ve observed in human cancers in mouse xenograft models of the disease.

Publications

  • Wagoner MP and Roopra A (2012). A REST derived gene signature stratifies glioblastomas into chemotherapy resistant and responsive disease. BMC Genomics. 13:686. PMCID: PMC3545737
  • Gunsalus KT, Wagoner MP, Meyer K, Potter WB, Schoenike B, Kim S, Alexander CM, Friedl A, and Roopra A (2012). Induction of the RNA regulator LIN28A is required for the growth and pathogenesis of RESTless breast tumors.Cancer Res. 72:3207-3216. PMCID: PMC3539431
  • Wagoner MP, Gunsalus KT, Schoenike B, Richardson AL, Friedl A, and Roopra A (2010). The transcription factor REST is lost in aggressive breast cancer. PLoS Genetics June 10 6:31000979. PMCID: PMC2883591
  • Potter WB, O’Riordan KJ, Barnett D, Osting SMK, Wagoner MP, Burger C, Roopra A (2010). Metabolic Regulation of neuronal plasticity by the energy sensor AMPK. PLoS ONE 5:e8996.
  • Wagoner MP, Ling K, and Anderson R (2008). Tracking the transport of E-cadherin to and from the plasma membrane. Methods in Molecular biology, 457:267-278. PMID:19066034
  • Sun Y, Ling K, Wagoner MP, and Anderson RA (2007). Type I„ PIP kinase is required for EGF-stimulated directional cell migration. J. Cell Biology 178:297-308. PMID: PMC2064448
  • Heck JN, Mellman DL, Ling K, Sun, Y, Wagoner MP, Schill NJ and Anderson RA (2007). A Conspicuous connection: Structure defines function for the phosphatidylinositol prosphate kinases family. Critical Rev. Biochem and Mol Biology.42:15-39. PMID:17364683
  • Ling K, Schill NJ, Wagoner MP, Sun Y, and Anderson RA (2006). Movin’ on up: the role of PtdIns(4,5)P(2) in cell migration. Trends Cell Biol. 16:276-284. Review. PMID:16616849